Truist Securities maintains Regeneron Pharmaceuticals at Buy, raises price target to $982 from $780
Truist Securities reaffirmed its Buy rating on Regeneron Pharmaceuticals and raised its price target to $982 from $780, citing a 5.8% upside from the Oct 30 close. Recent analyst notes have price targets ranging from $925 to $1175.
How this was made
The 30-second read
Why it matters
The higher target may attract new investors and support the stock price.
Market read
Analyst target upgrades can influence short‑term price action, especially for high‑visibility biotech stocks.
What to watch
Potential upcoming trial results or regulatory decisions not reflected in the target.
Background
Truist's analyst note updates price target based on recent company outlook.
Market effects
May boost biotech sector sentiment as analysts raise expectations.
Limited to US biotech equities.
Minor, confined to Regeneron and peers.
Counterpoint
Target raise could be premature if upcoming data disappoints.
Key entities
- analystTruist Securities
Equity research firm issuing the target raise.
- companyRegeneron Pharmaceuticals
Biotech firm receiving the upgraded target.
